Cassava’s Simufilam Continues To Alienate Investors Despite Some Phase II Alzheimer’s Promise
Executive Summary
The US firm is touting top-line data from an open-label Alzheimer’s disease trial as a net positive, but the lack of p-values and a declining trend in efficacy left some investors and analysts lukewarm.
You may also be interested in...
Cassava Dives Again After Investors Spooked By Alzheimer’s Drug Fraud Claims
Cassava’s claims that its drug reversed cognitive decline in Alzheimer’s patients are seen as "too good to be true" by skeptics. A statement by former lab services partner Quanterix has further undermined investor confidence.
Apellis Bounces Back After Needle Discontinuation Amid Syfovre Safety Concerns
Real-world cases of retinal vasculitis linked with Syfovre for geographic atrophy in age-related macular degeneration may have resulted from a material used in a specific filter needle, the US firm revealed, as analysts remained optimistic on the product.